WO1995003399A3 - Production method for preparation of disabled viruses - Google Patents

Production method for preparation of disabled viruses Download PDF

Info

Publication number
WO1995003399A3
WO1995003399A3 PCT/GB1994/001559 GB9401559W WO9503399A3 WO 1995003399 A3 WO1995003399 A3 WO 1995003399A3 GB 9401559 W GB9401559 W GB 9401559W WO 9503399 A3 WO9503399 A3 WO 9503399A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
gene
disabled
production
infectious
Prior art date
Application number
PCT/GB1994/001559
Other languages
French (fr)
Other versions
WO1995003399A2 (en
Inventor
Stephen Charles Inglis
Michael Edward Griff Boursnell
Claire Entwisle
Original Assignee
Cantab Pharma Res
Stephen Charles Inglis
Boursnell Michael E G
Claire Entwisle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939314912A external-priority patent/GB9314912D0/en
Priority claimed from GB9402065A external-priority patent/GB9402065D0/en
Application filed by Cantab Pharma Res, Stephen Charles Inglis, Boursnell Michael E G, Claire Entwisle filed Critical Cantab Pharma Res
Priority to AU71923/94A priority Critical patent/AU7192394A/en
Publication of WO1995003399A2 publication Critical patent/WO1995003399A2/en
Publication of WO1995003399A3 publication Critical patent/WO1995003399A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A transgenic species whose genome comprises a heterologous gene which is functionally equivalent to a non-retroviral virus gene which is essential for the production of normal infectious non-retroviral virus is taught. A method for manufacturing a mutant virus whose genome is disabled in respect of at least one virus gene essential for the production of infectious virus, such that the virus can infect normal cells and undergo replication and expression of viral antigen gene in those cells, but cannot produce normal infectious virus, which method comprises following the production of a transgenic animal whose genome comprises at least one heterologous gene which is functionally equivalent to the at least one virus gene, infecting at least one cell derived from the animal which contains the at least one heterologous gene with mutant virus; causing the at least one cell to express the heterologous gene so as to allow production of infectious virus particles containing the disabled gene; and harvesting infectious virus particles containing the disabled genome.
PCT/GB1994/001559 1993-07-19 1994-07-19 Production method for preparation of disabled viruses WO1995003399A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71923/94A AU7192394A (en) 1993-07-19 1994-07-19 Production method for preparation of disabled viruses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9314912.8 1993-07-19
GB939314912A GB9314912D0 (en) 1993-07-19 1993-07-19 Production method for preparation of defective viruses
GB9402065.8 1994-02-03
GB9402065A GB9402065D0 (en) 1994-02-03 1994-02-03 Production method for preparation of defective viruses

Publications (2)

Publication Number Publication Date
WO1995003399A2 WO1995003399A2 (en) 1995-02-02
WO1995003399A3 true WO1995003399A3 (en) 1995-03-16

Family

ID=26303257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/001559 WO1995003399A2 (en) 1993-07-19 1994-07-19 Production method for preparation of disabled viruses

Country Status (2)

Country Link
AU (1) AU7192394A (en)
WO (1) WO1995003399A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2211743A1 (en) 1995-02-21 1996-08-29 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
JP2004535151A (en) * 2000-10-10 2004-11-25 インスティトゥート フューア ヴィロロギー タイルレヒツフェヒゲス インスティトゥート アン デア ヴェテリネーアメディツィニーシェン ウニヴェルズィテート ヴィーン New system for evaluation of activity and / or specificity of viral components
US20050241011A1 (en) * 2002-04-09 2005-10-27 Allnut F C T Enclosed aquacultural systems for production of purified recombinant proteins
WO2011040527A1 (en) * 2009-09-30 2011-04-07 国立大学法人帯広畜産大学 TRANSGENIC BIRD CAPABLE OF EXPRESSING α-GALACTOSE EPITOPE, VIRUS, AND VACCINE
EP3739054A1 (en) * 2010-05-14 2020-11-18 Oregon Health & Science University Recombinant hcmv and rhcmv vectors encoding a heterologous human pathogen-specific antigen and uses thereof
AP2017009743A0 (en) 2014-07-16 2017-02-28 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
WO2016130693A1 (en) 2015-02-10 2016-08-18 Oregon Health & Science University Methods and compositions useful in generating non canonical cd8+ t cell responses
CA3005136A1 (en) 2015-11-20 2017-05-26 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
TN2019000124A1 (en) 2016-10-18 2020-10-05 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005263A1 (en) * 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005263A1 (en) * 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANSARDI, D. ET AL.: "Complementation of a Poliovirus defective genome by a recombinant Vaccinia virus which provides Poliovirus P1 capsid precursor in trans", JOURNAL OF VIROLOGY, vol. 67, no. 6, June 1993 (1993-06-01), pages 3684 - 3690 *
CUTHBERTSON, R. AND KLINTWORTH, G.: "Transgenic Mice - A gold mine for furthering knowledge in pathobiology", LABORATORY INVESTIGATION, vol. 58, no. 5, 1988, pages 484 - 502 *
FORRESTER, A. ET AL.: "Construction and properties of a mutant of Herpes simplex virus type 1 with glycoprotein H coding sequences deleted", JOURNAL OF VIROLOGY, vol. 66, no. 1, January 1992 (1992-01-01), pages 341 - 348 *

Also Published As

Publication number Publication date
AU7192394A (en) 1995-02-20
WO1995003399A2 (en) 1995-02-02

Similar Documents

Publication Publication Date Title
Clarke et al. Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses
Weaver et al. Genetic and fitness changes accompanying adaptation of an arbovirus to vertebrate and invertebrate cells
EP0953648A3 (en) Viral defective vaccine produced by transcomplementing cell line
Prassolov et al. New hepatitis B virus of cranes that has an unexpected broad host range
Kaper et al. Viral satellites: parasitic nucleic acids capable of modulating disease expression
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
CA2102918A1 (en) Genetic vaccine for immunodeficiency viruses
ATE120234T1 (en) HIV-3 RETROVIRUS AND ITS USE.
WO1995003399A3 (en) Production method for preparation of disabled viruses
WO2004022729A8 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
AU6790087A (en) Modification of plant viruses or their effects
Hall et al. Defective interfering particles produced during the replication of measles virus
WO2002000169A3 (en) Production of vaccines using transgenic plants
Marcus et al. Interferon induction by viruses. XIX. Vesicular stomatitis virus—New Jersey: high multiplicity passages generate interferon-inducing, defective-interfering particles
CA2099268A1 (en) Fusions of a viral protein and a destructive enzyme
WO2000023574A3 (en) Hepatitis a vaccines
Baric et al. A Sindbis virus variant with a cell-determined latent period
WO2000012677A3 (en) Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines
JP2019511208A5 (en)
WO1999057284A3 (en) Attenuated influenza viruses
ØRSTAVIK Susceptibility of continuous lines of monkey kidney cells to influenza and parainfluenza viruses in the presence of trypsin
AU8188187A (en) Viral vector and recombinant DNA coding, in particular, for the p25 protein of the virus that is a causal agent of aids, infected cell culture, protein obtained, vaccine and antibodies obtained
Avery Abortive infection of L cells by influenza virus: absence of virion RNA synthesis
EP0474868A4 (en) Method of producing core structure of retro virus and particle produced thereby
FR2580176A1 (en) AVIRULENT ANTIRABIC VACCINE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA